Trials / Completed
CompletedNCT01761565
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Talphera, Inc · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Single dose of SUF NT 15 mcg | |
| DRUG | 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2013-01-07
- Last updated
- 2015-10-01
- Results posted
- 2015-02-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01761565. Inclusion in this directory is not an endorsement.